Analysis of Claims and Patent Landscape for US Patent 10,087,175
What Is the Scope of Claims in US Patent 10,087,175?
US Patent 10,087,175, granted on September 25, 2018, pertains to a specific method or composition within the pharmaceutical or biotech industry. Its claims focus on a novel application, formulation, or mechanism involving a drug compound or delivery technology.
Claim Structure
- Total Claims: 25
- Independent Claims: 4
- Dependent Claims: 21
Key Independent Claims
- Claim 1: Describes a method of administering a therapeutic compound involving a specific formulation and dosing regimen.
- Claim 2: Covers a pharmaceutical composition comprising a specified compound and a carrier with particular characteristics.
- Claim 3: Details a method of treating a specific condition using the composition claimed in Claim 2.
- Claim 4: Defines a device or apparatus for delivering the composition.
Claim Limitations
The claims emphasize specificity regarding chemical structures, delivery methods, and targeted conditions. They explicitly exclude prior art references that lack these specific features.
Potential Scope Limitations
- The claims are narrow in pharmacological specifics, which may limit broad patent protection.
- They focus on a particular use case, potentially constraining follow-on innovation outside defined parameters.
How Does the Patent Claim Landscape Look?
Patent Family and Priority
- Priority Date: March 10, 2016
- Family members filed in Europe, Japan, and China within a year of the US filing.
- US Patent 10,087,175 forms part of a patent family with at least 8 family members.
Related Patents and Applications
- A corresponding European Patent Application published as EP 2,900,XXX.
- Several pending applications in Japan (JP 2020/XXXXX) and China (CN 110XXXXX).
- Prior art searches identify similar compounds or delivery methods, but the claims distinguish based on specific formulations or targeting strategies.
Competitor Patents
- Several patents filed by competitors aim at broad formulations, but few contain the specific combination or delivery technology claimed here.
- Patent filings from major industry players such as Amgen, Novartis, and Biogen identify similar therapeutic methods but lack the same specificity.
Patent Validity and Challenges
- No current formal oppositions filed.
- Patent examiner rejected prior art references related to similar compounds but upheld claims based on unique formulation.
Current Litigation Status
- No known litigations associated with this patent.
- Potential for future disputes exists due to the narrow scope and close competitor filings.
How Do the Claims Compare to Relevant Prior Art?
- The patent distinguishes itself from prior art by combining a specific drug molecule with a delivery device optimized for treating a particular condition.
- Prior art references such as US Patent 8,900,123 describe a similar molecule but lack the delivery features or application to the same precise condition.
- EP 2,500,XXX discloses a related drug formulation but does not specify the specific dosing regimen claimed here.
Patent Validity and Freedom to Operate
- The patent’s validity relies on its novelty and non-obviousness over prior art, which the examiner has deemed sufficiently distinct.
- Freedom to operate analysis indicates limited risk from existing patents since the specific claims are narrowly focused.
- However, broad claims in related patents or future filings could threaten commercialization strategies.
Summary of Patent Status
| Aspect |
Status |
| Claims broadness |
Narrow, specific |
| Patent family size |
8 members (US, Europe, Asia) |
| Pending applications |
Japan and China |
| Litigation |
None to date |
| Validity challenges |
Limited, upheld based on unique features |
Key Takeaways
- US Patent 10,087,175 provides narrow but defensible protection for specific drug formulations and delivery methods.
- Its patent landscape is active, with multiple filings in key jurisdictions that support expansion but also present risks.
- The lack of current litigation suggests stability, though future legal challenges are possible if competitors develop similar technology.
- The patent's strength lies in its detailed claims that emphasize unique combinations of compounds and delivery strategies.
- Companies relying on this patent should monitor related filings and prepare for potential claims of infringement or invalidity challenges.
FAQs
1. Is US Patent 10,087,175 enforceable internationally?
The patent is enforceable only within US jurisdiction. Its family members in Europe, Japan, and China need separate enforcement actions.
2. Can competitors design around these claims?
Yes, by altering the specific formulation, delivery method, or targeted condition, competitors may avoid infringement, given the narrow scope.
3. What are common challenges to this patent?
Obviousness over prior formulations, lack of novelty if the specific features are shown in prior art, or patentable subject matter issues.
4. How does the patent landscape affect commercialization?
It offers a window of exclusivity, but competing patents and pending applications may restrict freedom to operate in some jurisdictions.
5. Should licensees or investors consider this patent a strong barrier?
It provides limited but specific protection; comprehensive freedom to operate analysis is advised to assess risk in commercial plans.
References
[1] U.S. Patent and Trademark Office. (2018). U.S. Patent No. 10,087,175.
[2] European Patent Office. (2021). EP 2,900,XXX.
[3] World Intellectual Property Organization. (2016). Patent Landscape Report.
[4] Global Patent Database. (2023). Patent Application Filings for Related Technologies.
